Press Release – BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY TECHNOLOGY
BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British Columbia – (May 4th, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is […]
CSE Form 7 – Monthly Progress Report – BioMark Diagnostics Inc. – Mar 2022
FORM 7MONTHLY PROGRESS REPORT Name of Listed Issuer: BioMark Diagnostics Inc. _____ (the “Issuer”). Trading Symbol: BUX Number of Outstanding Listed Securities: 77,974,229 Date: April 4th, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. […]
BIOMARK TO PRESENT new CANCER SCREENING DATA using the LDTD-MS/MS technique AT THE ANNUAL ASMS Conference on Mass Spectrometry
BIOMARK TO PRESENT NEW CANCER SCREENING DATA USING THE LDTD-MS/MS TECHNIQUE AT THE ANNUAL ASMS CONFERENCE ON MASS SPECTROMETRY Vancouver, British Columbia – (April 27, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased […]
BioMark Monthly Progress Report April 4 2022
FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. BUX 77,974,229 April 4th 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation […]
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a […]
BIOMARK RECEIVES $825K GRANT TO DEVELOP ITS LIQUID BIOPSY ASSAY FOR LUNG CANCER SCREENING
Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) received funding to develop an early-stage lung cancer screening assay using BioMark’s proprietary liquid biopsy platform. The total sponsored research grant is about […]
BIOMARK REÇOIT UNE SUBVENTION DE 825 K $ POUR DÉVELOPPER SON TEST DE BIOPSIE LIQUIDE POUR LE DÉPISTAGE DU CANCER DU POUMON
Vancouver, Colombie-Britannique – (1er juin 2021) – BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) est heureuse d’annoncer aujourd’hui que sa filiale en propriété exclusive BioMark Diagnostic Solutions Inc. (“BDS”) a reçu un financement pour le développement d’un test de dépistage du cancer du poumon à un stade précoce en utilisant la technologie […]
BIOMARK ANNOUNCES CHANGE OF AUDITOR
Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announces that it has changed its auditors from Manning Elliott LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors […]
BIOMARK TO OPEN A DIAGNOSTIC LABORATORY IN QUÉBEC
Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy […]
BIOMARK ANNOUNCES EXERCISE OF WARRANTS AND GAIN DTC ELIGIBILITY FOR ITS COMMON SHARES
Vancouver, British Columbia – (April 21, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company’s private placement of units completed in April 2019, with the warrant […]
